New treatment targets in ankylosing spondylitis and other spondyloarthritides

Current Opinion in Rheumatology

Volumn 23, Issue 4, 2011, Pages 346-351

  Song, In Ho ^a   Poddubnyy, Denis ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

ankylosing spondylitis; B cells; interleukin; spondyloarthritis; T cells; treatment

Indexed keywords

ABATACEPT; BRIAKINUMAB; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 6; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RITUXIMAB; SAR 153191; SECUKINUMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; USTEKINUMAB;

ANKYLOSING SPONDYLITIS; ARTICLE; B LYMPHOCYTE; CELL STIMULATION; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG MEGADOSE; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; SPONDYLARTHRITIS; T LYMPHOCYTE; TREATMENT RESPONSE;

ANTIRHEUMATIC AGENTS; B-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; HUMANS; INTERLEUKINS; SPONDYLITIS, ANKYLOSING;

EID: 79958776237     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e328346f7fb     Document Type: Article

References (84)

1. Braun J, Sieper J. Ankylosing spondylitis. Lancet 2007; 369:1379-1390. (Pubitemid 46590387)
2. Zochling J, van der Heijde D, Burgos-Vargas R, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006; 65:442-452.
3. Haibel H, Rudwaleit M, Braun J, Sieper J. Six months open label trial of lefluno-mide in active ankylosing spondylitis. Ann Rheum Dis 2005; 64:124-126. (Pubitemid 40075288)
4. Haibel H, Brandt HC, Song IH, et al. No efficacy of subcutaneous metho-trexate in active ankylosing spondylitis: a 16-week open-label trial. Ann Rheum Dis 2007; 66:419-421. (Pubitemid 46579648)
5. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359:1187-1193. (Pubitemid 34304258)
6. Rudwaleit M, Listing J, Brandt J, et al. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 2004; 63:665-670. (Pubitemid 38658395)
7. Inman RD, Davis JC Jr, Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008; 58:3402-3412.
8. Appel H, Kuhne M, Spiekermann S, et al. Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitis. Arthritis Rheum 2006; 54:2845-2851. (Pubitemid 44497763)
9. Braun J, Bollow M, Neure L, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995; 38:499-505.
10. Bollow M, Fischer T, Reisshauer H, et al. Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis:cellularity correlates with the degree of enhancement detected by magnetic resonance imaging. Ann Rheum Dis 2000; 59:135-140. (Pubitemid 30305612)
11. Braun J, Bollow M, Eggens U, et al. Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. Arthritis Rheum 1994; 37:1039-1045. (Pubitemid 24222095)
12. Appel H, Loddenkemper C, Grozdanovic Z, et al. Correlation of histopatho-logical findings and magnetic resonance imaging in the spine of patients with ankylosing spondylitis. Arthritis Res Ther 2006; 8:R143.
13. Song IH, Heldmann F, Rudwaleit M, et al. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum 2010; 62:1290-1297.
14. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivobyachimeric mouse human monoclonal antibody to CD20. Blood 1994; 83:435-445. (Pubitemid 24030569)
15. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to antitumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54:2793-2806. (Pubitemid 44497758)
16. Rodriguez-Escalera C, Fernandez-Nebro A. The use of rituximab to treat a patient with ankylosing spondylitis and hepatitis B. Rheumatology (Oxford) 2008; 47:1732-1733.
17. Schleenbecker SK, Strock Müller K. Improvement of refractory ankylosing spondylitis in response to rituximab: a case report. Ann Rheum Dis 2008; 67:626.
18. Nocturne G, Dougados M, Constantin A, et al. Lack of efficacy of rituximab in spondyloarthropathies: data of 8 patients prospectively followed in the French AIR ('Auto-Immunity and Rituximab') registry. Ann Rheum Dis 2009; 68 (Suppl 3):626.
19. Wendling D, Auge B, Streit G, et al. Lack of short-term efficacy of rituximab upon symptoms of ankylosing spondylitis treated for an associated vasculitis. Joint Bone Spine 2008; 75:510-511.
20. Toussaint S, Karrer S, Wassenberg S. Successful treatment of neutrophilic granulomatous dermatitis with rituximabina patient with rheumatoid arthritis and spondylitis ankylosans: acase report. Ann Rheum Dis 2008;67 (Suppl 2):317.
21. Baeten D, Kruithof E, Breban M, Tak PP. Spondylarthritis in the absence of B lymphocytes. Arthritis Rheum 2008; 58:730-733. (Pubitemid 351364870)
22. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984; 27:361-368. (Pubitemid 14134775)
23. Van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005; 52:582-591. (Pubitemid 40216323)
24. Van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006; 54:2136-2146. (Pubitemid 44051069)
25. Davis JC Jr, Van Der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003; 48:3230-3236. (Pubitemid 37409337)
26. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358:676-688. (Pubitemid 351240747)
27. Lindholm C, Borjesson-Asp K, Zendjanchi K, et al. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol 2008; 35:826-833. (Pubitemid 351747123)
28. Leandro MJ, Cambridge G, Edwards JC, et al. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 2005; 44:1542-1545. (Pubitemid 41742472)
29. Jonsdottir T, Gunnarsson I, Risselada A, et al. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann Rheum Dis 2008; 67:330-334. (Pubitemid 351281266)
30. Lebrun C, Bourg V, Tieulie N, Thomas P. Successful treatment of refractory generalized myasthenia gravis with rituximab. Eur J Neurol 2009; 16:246-250.
31. Noel N, Monnet X, Angel N, et al. Life threatening steroid-resistant autoimmune anemia successfully treated with rituximab: a case report. Am J Hematol 2009; 84:193.
32. Pepper RJ, Fabre MA, Pavesio C, et al. Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production. Rheumatology (Oxford) 2008; 47:1104-1105. (Pubitemid 351865947)
33. Seo P, Specks U, Keogh KA. Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations. J Rheumatol 2008; 35:2017-2023.
34. Hertl M, Zillikens D, Borradori L, et al. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J Dtsch Dermatol Ges 2008; 6:366-373.
35. Mease P, Kavanaugh AF, Genovese MC, et al. Rituximab in psoriatic arthritis provides modest clinical improvement and reduces expression of inflammatory biomarkers in skin lesions. Arthritis Rheum 2010; 62 (Suppl):S818.
36. Zou J, Zhang Y, Thiel A, et al. Predominant cellular immune response to the cartilage autoantigenic G1 aggrecan in ankylosing spondylitis and rheumatoid arthritis. Rheumatology (Oxford) 2003; 42:846-855. (Pubitemid 37220933)
37. Zou J, Appel H, Rudwaleit M, et al. Analysis of theCD8\+Tcell responseto the G1 domain of aggrecan in ankylosing spondylitis. Ann Rheum Dis 2005; 64:722-729. (Pubitemid 40559299)
38. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005; 353:1114-1123. (Pubitemid 41317434)
39. Olivieri I, D'Angelo S, Mennillo GA, et al. Abatacept in spondyloarthritis refractory to tumour necrosis factor alpha inhibition. Ann Rheum Dis 2009; 68:151-152.
40. Berner B, Schedel J, Guenaydin I, et al. Abatacept for therapy of spondyloar-thritis due to therapy failure or contraindications of TNF-alpha antagonists. Ann Rheum Dis 2009; 68 (Suppl 3):623.
41. Compaore C, D'Agostino M-A, Belmiloud S, et al. Treatment of axial spondy-loarthritis (SpA) refractory to anti-TNFalpha with CTLA-4-Ig (abatacept): results of an open-label pilot study. Rev Rhumatisme 2009; 76:1132.
42. Song IH, Heldmann F, Rudwaleit M, et al. Treatment of active ankylosing spondylitis with abatacept: an open label 24-week study. Ann Rheum Dis 2010; 69 (Suppl 3):60.
43. Mease P, Genovese M, Gladstein G, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. 2011; 63:939-948.
44. Abrams JR, Kelley SL, Hayes E, et al. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med 2000; 192:681-694.
45. Francois RJ, Neure L, Sieper J, Braun J. Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases. Ann Rheum Dis 2006; 65:713-720. (Pubitemid 43799168)
46. Gratacos J, Collado A, Filella X, et al. Serum cytokines (IL-6,TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 1994; 33:927-931. (Pubitemid 24324807)
47. Tutuncu ZN, Bilgie A, Kennedy LG, Calin A. Interleukin-6, acute phase reactants and clinical status in ankylosing spondylitis. Ann Rheum Dis 1994; 53:425-426. (Pubitemid 24198933)
48. Claudepierre P, Rymer JC, Authier FJ, et al. A relationship between TGF-beta 1 or IL-6 plasma levels and clinical features of spondyloarthropathies. Br J Rheumatol 1997; 36:400-401. (Pubitemid 27352882)
49. Falkenbach A, Herold M. In ankylosing spondylitis serum interleukin-6 correlates with the degree of mobility restriction, but not with short-term changes in the variables for mobility. Rheumatol Int 1998; 18:103-106. (Pubitemid 28505331)
50. Bal A, Unlu E, Bahar G, et al. Comparison of serum IL-1 beta, sIL-2R, IL-6,and TNF-alpha levels with disease activity parameters in ankylosing spondylitis. Clin Rheumatol 2007; 26:211-215. (Pubitemid 46020247)
51. Brulhart L, Nissen MJ, Chevallier P, Gabay C. Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonists. Joint Bone Spine 2010; 77:625-626.
52. Henes JC, Horger M, Guenaydin I, et al. Mixed response to tocilizumab for ankylosing spondylitis. Ann Rheum Dis 2010; 69:2217-2218.
53. Shima Y, Tomita T, Ishii T, et al. Tocilizumab, a humanized antiinterleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis. Mod Rheumatol 2011 Feb 9. [Epub ahead of print]
54. Tanaka T, Kuwahara Y, Shima Y, et al. Successful treatment of reactive arthritis with a humanized antiinterleukin-6 receptor antibody, tocilizumab. Arthritis Rheum 2009; 61:1762-1764.
55. Ito H, Takazoe M, Fukuda Y, et al. A pilot randomized trial of a human antiinterleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004; 126:989-996; discussion 47. (Pubitemid 38451170)
56. Bettelli E, Korn T, Oukka M, Kuchroo VK. Induction and effector functions of T(H)17 cells. Nature 2008; 453:1051-1057. (Pubitemid 351871737)
57. Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005; 6:1123-1132. (Pubitemid 41541790)
58. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007; 8:942-949. (Pubitemid 47300008)
59. Shen H, Goodall JC, Hill Gaston JS. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum 2009; 60:1647-1656.
60. Leipe J, Grunke M, Dechant C, et al. Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum 2010; 62:2876-2885.
61. Kagami S, Rizzo HL, Lee JJ, et al. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol 2010; 130:1373-1383.
62. Liu ZJ, Yadav PK, Su JL, et al. Potential role of Th1 7 cells in the pathogenesis of inflammatory bowel disease. World J Gastroenterol 2009; 15:5784-5788.
63. Wendling D, Cedoz JP, Racadot E, Dumoulin G. Serum IL-17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis. Joint Bone Spine 2007; 74:304-305. (Pubitemid 46720037)
64. Jandus C, Bioley G, Rivals JP, et al. Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthri-tides. Arthritis Rheum 2008; 58:2307-2317.
65. Wang X, Lin Z, Wei Q, et al. Expression of IL-23 and IL-17 and effect of IL-23on IL-17 production in ankylosing spondylitis. Rheumatol Int 2009; 29:1343-1347.
66. Mei Y, Pan F, Gao J, et al. Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis. Clin Rheumatol 2011; 30:269-273.
67. Appel H, Heydrich R, Loddenkemper C, et al. In situ detection of IL-17 secreting cells in the bone marrow of facet joints obtained from patients with ankylosing spondylitis. Arthritis Rheum 2008; 58 (Suppl):S351.
68. Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010; 2:52ra72.
69. Baeten D, Sieper J, Emery P, et al. The anti-IL1 7A monoclonal antibody secukinumab (AIN457) showed good safety and efficacy in the treatment of active ankylosing spondylitis. Arthritis Rheum 2010; 62:3840.
70. Parham C, Chirica M, Timans J, et al. A receptor for the heterodimericcytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol 2002; 168:5699-5708. (Pubitemid 34556153)
71. Matsui M. Roles of the novel interleukin-12-associated cytokine, interleukin-23, in the regulation of T-cell-mediated immunity. Hepatol Res 2007; 37 (Suppl 3):S310-S318. (Pubitemid 47570638)
72. Appel H, Rose A, Maier R, et al. In situ analysis of IL-23 secreting cells in the spine of patients with ankylosing spondylitis. Ann Rheum Dis 2010; 69 (Suppl 3):104.
73. Burton PR, Clayton DG, Cardon LR, et al. Association scan of 14 500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet 2007; 39:1329-1337. (Pubitemid 350041542)
74. Rueda B, Orozco G, Raya E, et al. The IL23R Arg381Gln nonsynonymous polymorphism confers susceptibility to ankylosing spondylitis. Ann Rheum Dis 2008; 67:1451-1454.
75. Rahman P, Inman RD, Gladman DD, et al. Association of interleukin-23 receptor variants with ankylosing spondylitis. Arthritis Rheum 2008; 58:1020-1025. (Pubitemid 351564003)
76. Karaderi T, Harvey D, Farrar C, et al. Association between the interleukin 23 receptor and ankylosing spondylitis is confirmed by a new UK case-control study and meta-analysis of published series. Rheumatology (Oxford) 2009; 48:386-389.
77. Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007; 356:580-592. (Pubitemid 46220818)
78. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371:1665-1674. (Pubitemid 351671883)
79. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371:1675-1684. (Pubitemid 351671884)
80. Kimball AB, Gordon KB, Langley RG, et al. Efficacy and safety of ABT-874, a monoclonal antiinterleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trial. J Am Acad Dermatol 2011; 64:263-274.
81. Griffiths CE, Strober BE, van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010; 362:118-128.
82. Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009; 373:633-640.
83. Mannon PJ, Fuss IJ, Mayer L, et al. Antiinterleukin-12 antibody for active Crohn's disease. N Engl J Med 2004; 351:2069-2079. (Pubitemid 39482500)
84. Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008; 135:1130-1141.